CINV


Also found in: Acronyms.

CINV

chemotherapy-induced emesis

An adverse effect of many chemotherapeutics, which is usually self-limited and rarely life-threatening.
 
Highly emetogenic
Cisplatin, carmustine, dacarbazine, dactinomycin, mechlorethamine (nitrogen mustard), streptozocin.
 
Moderately emetogenic
Azacitidine, arparginase, carboplatin, cyclophosphamide, doxorubicin, mitomycin.
 
Management
Dopamine (D2 high-dose metoclopramide), serotonin (5-HT3 receptor antagonists—e.g., ondansetron),
References in periodicals archive ?
Finding affordable healthcare solutions that are effective and reduce or delay CINV in patients undergoing chemotherapy may make a significant impact on health outcomes and quality of life.
Since NK1 receptor antagonists are used in combination with 5-HT3 receptor antagonists, CINVANTI offers a strong strategic and operational fit with Heron's existing commercial product, SUSTOL[R], our extended-release, injectable product that incorporates the 5-HT3 receptor antagonist granisetron and is also indicated for the prevention of CINV.
3] receptor antagonist, Palonosetron with high receptor binding affinity and long elimination half-life of 40 hours is found to be effective in delayed CINV also.
CINV is one of the most common side effects of chemotherapy.
for a treatment combining netupitant and palonosetron for the prevention of acute and delayed nausea and vomiting associated with CINV.
Being female is the strongest predictor for PONV (27) and CINV.
SUSTOL is the first approved therapy that utilises the company's Biochronomer polymer-based drug delivery technology, allowing it to maintain therapeutic levels of granisetron for >=5 days, covering both the acute and delayed phases of CINV.
Although paediatric patients were administered a higher dose per kg than adults to prevent CINV, palonosetron safety profile was consistent with its established profile in adults.
The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids.
While this study demonstrated that pediatric patients require a higher palonosetron dose based on weight than adults to prevent CINV, the safety profile for ALOXI was confirmed as being consistent with the established profile in adults.